March 27, 2017 / 11:40 AM / 8 months ago

BRIEF-Foamix reports topline results from phase 3 trials for fmx101

March 27 (Reuters) - Foamix Pharmaceuticals Ltd:

* Foamix reports topline results from phase 3 trials for fmx101 in patients with acne

* Foamix Pharmaceuticals - in intent-to-treat analysis, FMX101 demonstrated statistical significance compared to vehicle on both co-primary endpoints in trial 05

* Foamix - in intent-to-treat analysis, FMX101 did not demonstrate statistical significance on one of two co-primary endpoints in trial 04

* Foamix Pharmaceuticals Ltd - FMX101 was generally safe and well-tolerated Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below